Refine by
Cancer Tissue Articles & Analysis
40 news found
This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative diseases. For example, Multiple Sites of Normal Brain Tissue Microarray, 80 Cases, 26 Cores (Catalog NO. ...
This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug discovery, cancer research, and tissue engineering. The Centre of Excellence will house state-of-the-art CELLINK bioprinters, including the flagship BIO X6 and BIONOVA X bioprinters, a range of bioinks and the leading ...
ByCELLINK
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed ...
xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer. As the knowledge of cancer and ...
ByxCures
National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). ...
Patients with incurable breast cancer could potentially benefit from new Welsh-led research, latest evidence suggests. ...
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer ...
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast ...
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence. ...
Called the Sentry System, it captures telltale signs of cancerous cells. The probe shines a light onto brain tissue, and then notes wavelength shifts. Those shifts reflect the molecular makeup of cancerous tissues, distilling a fingerprint of sorts for different tissue types and molecular signatures of ...
Reveal’s technology can detect cancerous tissue that has been left behind using traditional imaging methods, combining an AI engine that provides real-time tissue characterization and intuitive optical probes that can be manipulated easily in a variety of surgical settings. ...
Importantly, Perimeter’s novel imaging technology with AI fits into the routine surgical process with no additional imposition to the patient as it examines a tissue sample that is already being extracted. There is a strong medical need for tools to help surgeons identify if we have adequately removed the cancerous tissue real-time in the ...
Avelas is developing pegloprastide (AVB-620), a novel fluorescent imaging agent used in combination with a fluorescence camera system, which has FDA Breakthrough Therapy Designation, for the intraoperative detection and visualization of positive margins during breast cancer surgery. The goal of intraoperative image-guided surgery with pegloprastide is to increase the precision ...
The test is the first and only FDA-approved next-generation sequencing (NGS) CDx on formalin-fixed, paraffin-embedded (FFPE) tissue for determining RYBREVANT eligibility in patients whose disease has progressed on or after platinum-based chemotherapy. Lung cancer is the leading cause of cancer deaths worldwide.1 EGFR mutations are an important ...
The company's approach also demonstrates high levels of accurate detection of early-stage (I, II) colorectal cancer at 89% sensitivity and 97% specificity. Universal DX is specially focused on identifying cancer in its earliest stages, so that the disease can be cured, and even in its pre-cancerous stage, when cancer can be ...
In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In ...
OnLume raised over $7 Million in this financing, adding to a $2 Million Phase II SBIR grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), awarded in late 2020. ...
After the surgeon removes the cancerous tumor during surgery, CHCP is subsequently sprayed at the surgical margins to target any remaining cancerous tissue or cells, thus reducing the chances of cancer recurrence. ...
This discovery is that there is a marked difference in the relaxation time of the NMR (MRI) signals between normal and cancerous tissues of the same type, as well as between different types of normal tissues. ...